Tag:

Roche

Latest Headlines

Latest Headlines

Merck and Roche prep breast cancer data for promising PD-1 drugs

As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer by the end of the year.

Same-day approvals send Roche, Boehringer to IPF market battle

There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.

Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%

Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.

Flailing Wilex finds a lifeline as Roche steps in with an ADC deal

Germany's Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.

Novartis, Roche chiefs still top list of highest-paid Swiss managers despite exec-pay uproar

Swiss citizens may have recently voted for some of the world's tightest controls on executive pay. But did that keep the Roche and Novartis pharma chiefs from pocketing more than 13 million Swiss francs ($13.6 million) last year? Not according to a new study.

With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells

A team from the Singapore-based Agency for Science, Technology and Research has found that a component of green tea has the potential to act as a nano-sized drug delivery vehicle to encapsulate proteins used to fight cancer.

Roche says specialty distributors can better protect supply chain from counterfeiters

Counterfeiters managed to get fakes of some of Roche's ($RHHBY) top-selling cancer drugs, including Herceptin and MabThera/Rituxan, into the European market this summer. This, among other issues, has motivated Roche's  Genentech  to have specialty distributors handle these recently conterfeited drugs, as well as Avastin. This decision has outraged some hospitals.

Report: Financial conflicts sway studies of flu fighters Tamiflu and Relenza

A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?

Peg cancer drug prices to effectiveness, '60 Minutes' interviewee suggests

On  " 60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.

Top women in biotech 2014

Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...